Eurofins Scientific stock drops on weaker organic growth

Published 30/01/2025, 10:26
© Reuters.

Investing.com -- Shares of Eurofins Scientific (EPA:ERF) fell by 2.3% as the company reported weaker organic growth in the fourth quarter. Although full-year revenues were broadly in line with consensus estimates, Eurofins’ organic growth for the year was slightly below expectations at 4.7%, compared to the consensus of 5.1% and Jefferies estimate of 4.5%.

The fourth quarter saw organic growth slow to 3.3%, suggesting an underlying growth rate of approximately 2% when accounting for working days benefits.

Despite the slowdown in organic growth, Eurofins’ adjusted EBITDA and adjusted earnings per share (EPS) were positive. The adjusted EBITDA for the fiscal year matched consensus estimates at €1,552 million, with a margin of 22.3%, showing a 140 basis points improvement year-on-year (YoY). Adjusted EPS outperformed consensus by 5%, reaching €3.37, a 24% increase YoY.

The company’s free cash flow (FCF) was notably strong, reported at €954 million, up 52% YoY, surpassing both Jefferies’ and the company’s own guidance. This was partly due to a significant working capital inflow and slightly lower net capital expenditures. Eurofins also reported a net debt to EBITDA ratio of 1.9x, within their target range.

Looking ahead, Eurofins provided looser guidance for fiscal year 2025, targeting mid-single-digit organic growth, with additional contributions from mergers and acquisitions (M&A), and improvements in EBITDA margin and FCF. However, the company has moved away from its previous numerical EBITDA/FCF targets.

For fiscal year 2027, Eurofins reiterated an average of 6.5% organic growth and confirmed a 24% EBITDA margin target, although it has abandoned its €10 billion revenue goal and now expects further increases in free cash flow to be more back-end weighted.

Jefferies commented on the results, stating: "Headline FCFF also looks strong, but supported by big WC swing and easing capex, & we expect some questions on sustainability/quality of beat."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.